It's a bumper Wednesday with two heavy-hitting pharma R&D white papers being published simultaneously. In no particular order, I strongly recommend setting aside some time to read through the latest from Deloitte and IQVIA Institute for Human Data Science. Both leverage data from across Norstella in very creative ways to communicate the challenges and opportunities facing biopharma innovators and investors. There's too much to unpack for any hot takes, but the obesity-driven uptick in productivity is a clear theme. Our industry has long been characterized by the outsized success of a select few therapies, and the GLP-1 era is very much upon us. Of course, Citeline also released its own R&D report earlier this month by the inimitable Ian Lloyd. I have been busy digesting this and updating various slides with his latest nuggets. Taken together, all three pieces of work add tremendous value to R&D decision makers and how to reconcile the abundance of drug discovery work globally with finite budgets and patient availability. Links below! Citeline Pharma R&D Annual Review: https://lnkd.in/euFDycTZ Deloitte Measuring the Return from Pharmaceutical Innovation: https://lnkd.in/eVcyNy2n IQVIA Global Trends in R&D: https://lnkd.in/eReVfPN8
